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Post-transcriptional gene regulation is prevalent in the
nervous system, where multiple tiers of regulatory com-
plexity contribute to the development and function of
highly specialized cell types. Whole-genome studies in
Drosophila have identified several hundred genes con-
taining long 39 extensions in neural tissues. We show
that ELAV (embryonic-lethal abnormal visual system) is
a key mediator of these neural-specific extensions. Mis-
expression of ELAV results in the ectopic synthesis of
long messenger RNAs (mRNAs) in transgenic embryos.
RNA immunoprecipitation assays suggest that ELAV di-
rectly binds the proximal polyadenylation signals of many
target mRNAs. Finally, ELAV is sufficient to suppress
39 end formation at a strong polyadenylation signal
when tethered to a synthetic RNA. We propose that this
mechanism for coordinating 39 UTR extension may be
generally used in a variety of cellular processes.
Supplemental material is available for this article.
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Regulatory elements located within 39 untranslated re-
gions (UTRs) provide an assembly platform for RNA-
binding proteins andmicroRNAs, which control stability,
subcellular localization, and translatability of messenger
RNAs (mRNAs) (Martin and Ephrussi 2009; Fabian et al.
2010). Alternative 39 end formation—i.e., usage of differ-
ent polyadenylation [poly(A)] sites—results in the syn-
thesis of multiple mRNA isoforms, differing only in the
lengths of their 39UTRs. Alternative cleavage and poly(A)
(APA) is a major mechanism for the correct spatial and
temporal control of gene expression during development
(Di Giammartino et al. 2011; Proudfoot 2011). Approxi-
mately half of all expressed genes are thought to be
subject to APA in humans, mice (Tian et al. 2005), and
Drosophila (Smibert et al. 2012), often in a tissue-specific
manner (Zhang et al. 2005; Wang et al. 2008).
APA-mediated 39 UTR shortening has been linked to
cell proliferation, oncogenic transformation, pluripotency,
lymphocyte activation, and neuronal activation (Takagaki
et al. 1996; Flavell et al. 2008; Sandberg et al. 2008; Ji and
Tian 2009; Mayr and Bartel 2009). Proximal poly(A) sites
are thought to enhance gene expression by minimizing
destabilizing elements (e.g., microRNA recognition sites)
that are likely to occur in extended 39 UTRs. Conversely,
longer 39 UTRs have been observed in later developmen-
tal stages and differentiated tissues (e.g., Ji et al. 2009;
Hilgers et al. 2011). Recent studies have shown that
hundreds of genes undergo APA-mediated 39 UTR exten-
sion during the course of Drosophila development. Many
of these genes exhibit staggered 39 extensions, with
intermediate mRNA isoforms appearing during early
stages of neurogenesis, and longer isoforms appearing at
later stages. Strikingly, expression of the extended tran-
scripts is predominantly restricted to the nervous system
(Hilgers et al. 2011; Smibert et al. 2012).
The function of the 39 UTR extensions is currently
unknown. Extended transcripts are enriched in conserved
regulatory signals, including binding sites for microRNAs
and RNA-binding proteins such as Pumilio. Long mRNA
isoforms possess a larger post-transcriptional potential
than their short counterparts, which might reflect their
role in neural-specific processes. Many of the genes that
are subject to neural-specific APA are required for ner-
vous system function. It has been proposed that 39 exten-
sions mediate a specific function within the neuron, such
as mRNA transport along axons (Hilgers et al. 2011).
In this study, we investigate the basis for the coordinate
appearance of extended 39 UTRs in neural tissues. The
pan-neuronal RNA-binding protein ELAV (embryonic-
lethal abnormal visual system) regulates mRNA process-
ing in a neural-specific manner. ELAV is required for
alternative splicing of armadillo (arm), neuroglian (nrg),
and erect wings (ewg), resulting in neural-specific iso-
forms (Lisbin et al. 2001; Soller and White 2003). ELAV
also binds to its own mRNA to regulate ELAV levels
(Samson 1998; Borgeson and Samson 2005). Here, we
show that ELAV regulates APA of multiple mRNAs in
the developing nervous system. We found that extended
mRNA isoforms are specifically expressed in cells where
ELAV protein is present. There is a dramatic reduction of
these isoforms in elav mutants. Furthermore, ectopic
expression of ELAV in nonneural embryonic tissues in-
duces ectopic 39 extension. RNA immunoprecipitation
(RIP) assays identify ELAV binding in the vicinity of the
proximal poly(A) signal of extended mRNAs. Finally,
tethering ELAV to an exogenous mRNA triggers tran-
scriptional readthrough several kilobases beyond a strong
poly(A) signal. These data provide the first evidence that
ELAV coordinates the expression of 39 UTR extensions
during neural development. We propose that similar
mechanisms are used in other metazoan processes.
Results and Discussion
We showed previously that long 39 UTR extensions are
first synthesized 4–6 h after egg laying (AEL) and specif-
ically localize to the nervous system. Computational
analyses revealed that these extensions are enriched in
conserved U-rich sequences; i.e., putative ELAV-binding
sites (EBSs) (Hilgers et al. 2011; Smibert et al. 2012). The
panneuronal protein ELAV is a known regulator of nu-
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clear pre-mRNA processing mediated by degenerate, low-
complexity sequences (Soller and White 2004). We there-
fore sought to determine whether ELAVmight be involved
in the regulation of APA-mediated 39 extensions.
Coexpression of ELAV and 39 extensions
We performed RNA in situ hybridization coupled to
antibody staining to visualize the distribution of ELAV
protein and extended 39 UTRs. Particular efforts focused
on brain tumor (brat), which is subject to two distinct
APA processes, producing three brat isoforms: a short
4.5-kb transcript bearing a 1.3-kb 39 UTR (universal), an
intermediate 6.4-kb transcript that is produced after 4 h
AEL (extension 1), and finally, a fully extended 11.7-kb
transcript that appears several hours later in development
(extension 2) (Fig. 1A; Hilgers et al. 2011).
ELAV protein is present in newborn neurons at the
onset of embryonic stage 10 (Fig. 1B; Robinow and White
1991). A hybridization probe detecting all brat isoforms
(universal) (Fig. 1A) showed expression throughout the
ventral nerve cord primordium in stages 10 and 11 (Fig.
1B–D). A probe specific to the intermediate brat 39 isoform
(extension 1) detected nascent transcripts only in those
few neurons containing ELAV at the onset of stage 10
(Fig. 1B, arrows). At later stages, ELAV protein localized
to clusters of neurons as they were born. There was
a coincident appearance of brat extensions in the same
pattern (Fig. 1C,D). At embryonic stage 13, short brat
mRNA isoforms are found throughout the embryonic
brain and ventral nerve cord. As seen at earlier stages,
brat extensions were detected only in ELAV-expressing
neurons (Supplemental Fig. S1A).
ELAV exhibits weak and transient expression in em-
bryonic neuroblasts and glial cells (Berger et al. 2007).
brat extension 1 was detected (at low levels) in these
cells, but not the full-length mRNA containing extension
2. Rather, the longest form of brat was restricted to
neurons that express high levels of ELAV (Fig. 1E). These
observations suggest a dosage relationship between the
levels of ELAV and the extent of APA-mediated 39 UTR
extension. Similar results were observed for additional
APA-regulated genes (hrb27C, musashi [msi], scratch,
and elav) (Supplemental Fig. S1B–E), suggesting a broad
correlation between ELAV and 39 extensions.
ELAV mutants lack 39 extensions
To investigate the causal link between ELAV and 39 ex-
tensions, we examined brat expression in elav mutants.
We used the null allele elav5 (Yao et al. 1993) as well as a
deficiency encompassing elav [Df(elav)]. ELAV was ab-
sent in both mutants. Short (universal) brat isoforms were
present and not detectably affected. However, extended
brat isoforms were barely detectable in elav mutants
(Fig. 2B) in comparison with their heterozygous siblings
(Fig. 2A; Supplemental Fig. S2A). We obtained similar
results for hrb27C and scratch (Supplemental Fig. S2B,C).
We next performed RT-qPCR on single 10- to 12-h elav5
mutant embryos. elav mRNA levels were measured in
each embryo to identify null mutants and heterozygous
control embryos. Total mRNA levels of brat, argonaute1
(ago1), nejire (nej), pumilio (pum), and IGF-II mRNA-
binding protein (imp) were unchanged or elevated in mu-
tant embryos. In contrast, extended isoforms were dra-
matically reduced for each of these genes in elavmutants
(Fig. 2C; Supplemental Fig. S2D). We therefore conclude
that ELAV is necessary for the synthesis of many of the
previously identified 39 UTR extensions.
Misexpression of ELAV results in ectopic 39 extensions
We examined the consequences of misexpressing ELAV
on the APA of target transcripts. We used the pan-
ectodermal 69B-Gal4 driver in combination with either
UAS-elav orUAS-GFP. Neurons were distinguished from
nonneuronal cells that ectopically express ELAV using
the anti-horseradish peroxidase (anti-HRP) antibody, which
specifically stains neural membranes (Fig. 3A–D; Snow
et al. 1987).
Ectopic expression of ELAV in nonneural ectodermal
cells resulted in the appearance of brat mRNAs contain-
ing extended 39 UTRs. Cells containing high levels of
Figure 1. Coexpression of 39 extensions and ELAV. (A) Schematic
representation of the 39 end of the gene brat. In situ hybridization
probes were designed to detect all brat RNA isoforms (universal),
both extended isoforms (extension 1), or exclusively the longest brat
isoform (extension 2). Bar, 1 kb. (B–E) Double fluorescent in situ
hybridization for bratmRNA using probes indicated in A, combined
with antibody staining against ELAV protein. (B–D) Single confocal
sections of the posterior end of stage 10 (B,C) and stage 11 (D)
embryos. Nuclei were stained with DAPI. Lateral view; anterior is to
the left, and dorsal is to the top. While the universal probe detects
bratmRNA throughout the presumptive nerve cord, brat extensions
first appear in cells at the onset of ELAV protein expression (B,
arrows), and expression of extensions continues to coincide with
ELAV expression as it expands in the ventral nerve cord (C,D). (E)
Single confocal section of the developing CNS in a stage 13 embryo.
Ventral view; anterior is to the left. In cells in which ELAV protein
is weakly expressed (magnified cutout), extension 1 expression is
reduced in comparison with neighboring cells showing high ELAV
expression, and extension 2 is altogether absent. Note that Elav
protein is mostly restricted to the nucleus, whereas the detected
RNAs are also present in the cytoplasm.
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ELAV exhibited the longest brat isoform (extension 2)
(Fig. 3B9,D9, arrows and magnified cutouts), whereas only
the intermediate isoform (extension 1) was observed in
cells with low levels of ELAV (Supplemental Fig. S3A).
Control embryos that express GFP did not display such
changes in brat expression (Fig. 3A9,C9; Supplemental Fig.
S3B). Our results suggest that ELAV functions in a dose-
dependent fashion to regulate brat APA. This is consis-
tent with the differential expression of the brat exten-
sions 1 and 2 in normal neural tissues containing either
low or high levels of ELAV (see Fig. 1).
ELAV binds in the vicinity of proximal poly(A) signals
We next ascertained whether ELAV physically associates
with transcripts containing 39 extensions using RIP
assays. Nuclear extracts of 8- to 12-h AEL embryos were
sonicated in order to obtain RNA fragments measuring
100–300 nucleotides (Supplemental Fig. S4B). ELAV-
containing riboprotein complexes were purified using
monoclonal anti-ELAV antibodies. As a positive control, we
determined whether ELAV binds to known target genes:
ewg, nrg, and elav (Lisbin et al. 2001; Soller and White
2003; Borgeson and Samson 2005). qPCR was used to
amplify the regions flanking the EBS and coding sequences
(CDS) in these genes (Fig. 4A). We observed that EBS-
containing regions, but not control CDS regions, were
highly enriched for ELAV (Fig. 4C). These results indicate
that the RIP assay selectively identifies EBSs in vivo.
To determine whether ELAV is directly involved in the
synthesis of 39 extensions, we designed qPCR primers
that amplify a region of the mRNA located immediately
downstream from proximal poly(A) signals (Fig. 4B, EBS).
We found that ELAV associates with the extended mRNA
isoforms of brat, ago1, pum, msi, hephaestus (heph), and
fasciclin 1 (fas1) near the proximal poly(A) signal. We
found little or no association within control regions,
including coding, intronic, or short 39 UTR sequences,
or at the distal-most poly(A) signals (Fig. 4D; Supple-
mental Fig. S4C–E). ELAV was also detected within the
39 UTR extensions (Fig. 4C; Supplemental Fig. S4C),
including significant binding immediately 39 of the
intermediate brat isoform (EBS2) (Fig. 4B,D). This sug-
gests that ELAV controls phased elongation of the brat 39
UTR in a dose-dependent manner, consistent with the in
vivo correlation between the distribution of ELAV and
the appearance of the intermediate and long brat iso-
forms (see Figs. 1, 3).
Based on RIP assays, seven of nine putative target genes
exhibited significant ELAV binding at proximal poly(A)
signals (Fig. 4; Supplemental Fig. S4). The absence of
binding at the remaining genesmight be due to technical
issues or reflect a regulatory cascade whereby ELAV con-
trols one or more intermediate genes. We favor the former
explanation, since previous studies suggest that neural-
specific genes exhibit highly synchronous 39 extension
during development (Hilgers et al. 2011).
Figure 2. Depletion of 39 extensions in elav mutants. (A,B) Double
fluorescent in situ hybridization for short (universal) and long (ex-
tension 2) brat mRNA isoforms, combined with antibody staining
against ELAV protein. Nuclei were stained with DAPI. Shown are
projections of consecutive confocal sections of the ventral nerve
cord of stage 13 embryos. Lateral view; anterior is to the left and
dorsal is to the top. (A) In heterozygous control embryos, ELAV
protein is expressed in neurons throughout the ventral nerve cord.
(B) In a hemizygous elav mutant, ELAV protein is absent. Although
the bulk of brat mRNA (universal) is not detectably affected in the
mutant, the longest brat isoform (extension 2) is depleted in elav5
compared with the control. (C) Quantification of indicated tran-
scripts by qPCR using primer combinations detecting all isoforms
(UTR) or specific to the long isoforms (ext). RNAwas extracted from
heterozygous control (elav5/+) or elav mutant (elav5) embryos.
Levels were normalized to rp49 RNA. For each primer pair, expression
in control embryos was set to the value 1. In elavmutants, the overall
expression of the genes brat, ago1, nej, pum, and imp is higher or not
affected compared with control embryos. However, longer isoforms
are strongly depleted in the mutants. Error bars represent mean 6 SD
of six embryos for each genotype.
Figure 3. Misexpression of ELAV results in ectopic 39 extensions. In
situ hybridization against the longest brat isoform, combined with
antibody staining in embryos expressing UAS-GFP (A,A9,C,C9) or
UAS-elav (B,B9,D,D9) under control of the 69B-Gal4 driver. The top
and bottom panels show a lateral and a ventral view of stage 13
embryos, respectively. (B) Nonneural cells ectopically expressing
ELAV can be distinguished by the absence of anti-HRP signal (e.g.,
arrows). (A,A9) brat extension 2 is only detected in the ventral nerve
cord (VNC) and the embryonic brain (eb) in control embryos. (B,B9)
In embryos ectopically expressing ELAV, ectopic brat extensions can
be detected in the ectoderm (arrows, and arrows in the magnified
cutout). (C,C9) brat extension 2 is detected in the ventral nerve cord
and peripheral neurons in control embryos (arrowheads in the
magnified cutout). In embryos where ELAV is expressed throughout
the ectoderm (D; ec), brat extension is ectopically expressed in cells
that contain high levels of ELAV protein (D9 and magnified cutout).
ELAV mediates 39 extension in neurons
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Tethering ELAV to a synthetic RNA causes
transcriptional readthrough
To test whether physical association of ELAV in the
vicinity of the proximal poly(A) site is sufficient to trigger
39 extension, we used a tethering assay in Drosophila S2
cells (Pillai et al. 2004). A reporter mRNA was created
that contains the firefly luciferase CDS, followed by the
SV40 late poly(A) signal and a GFP CDS. This construct
carries five hairpins (BoxB sites) that are bound with high
affinity by the N-peptide of bacteriophage l (lN). ELAV
was coexpressed as a fusion protein with the lN peptide
to tether ELAV to the luciferase transcript (Fig. 5A).
Tethering lN-ELAV, but not lN alone, to the luciferase
reporter caused transcription of GFP sequences 39 of the
poly(A) signal. A control mRNA devoid of the BoxB-
tethering sites [BoxB ()] was not significantly extended
(Fig. 5B). Furthermore, tethering the RNA-binding pro-
tein Ago1 to the reporter had no effect on GFP expression,
while Sex lethal (Sxl) promoted only modest extension
beyond the poly(A) site (Fig. 5B; Supplemental Fig. S5).
These experiments show that ELAV binding is sufficient
to bypass a strong poly(A) signal, resulting in the synthe-
sis of a 39 extension.
Here we presented evidence that the RNA-binding
protein ELAV regulates 39 UTR extension during neuro-
nal differentiation. Past studies have documented a role
for ELAV in the regulation of splicing; the present study
shows that it is also crucial for the synthesis of a battery
of extended 39 UTRs. A variety of evidence suggests that
ELAV functions by suppressing proximal poly(A), thereby
permitting readthrough of elongating polymerase II com-
plexes. RIP assays show that ELAV binds at proximal
poly(A) signals, and tethering assays indicate that this
binding is sufficient to trigger 39 extension of an exoge-
nous gene in a heterologous system. We propose that
Figure 4. ELAV RIP assays identify 39 extended mRNAs. (A) Gene models of known ELAV targets. The locations of EBSs are indicated as red
boxes. qPCR primers were designed to detect a region in the CDS as a negative control, a region encompassing the EBS, or a region located more
distally within the extension (ext 2). (B) Gene models of three candidates for ELAV binding at the 39 extension. qPCR primers were designed to
detect a region in the CDS, a region immediately downstream from the short UTR (EBS), or the first portion of a more distal extension (EBS2).
Bar, 1 kb. qPCR amplicons (black bars) are 60–80 base pairs (bp) in length and are not represented to scale. (C,D) ELAV binds specifically to
39 UTR extension sequences in the vicinity of poly(A) signals. RIP analysis was performed on 8- to 12-h embryos using either anti-ELAV
antibodies or control IgGs. RNA from ELAV immunoprecipitates was assayed by qPCR for the regions indicated in A and B and compared with
RNA from total sonicated nuclei (input). Error bars represent mean 6 SD of four separate immunoprecipitation reactions on independently
prepared nuclei.
Figure 5. ELAV is sufficient to promote 39 extension in a heterolo-
gous system. (A) Schematic of the tethering experiment. A luciferase
ORF was placed upstream of BoxB sequences (BoxB) and the SV40
late poly(A) signal. Downstream, a GFP ORF represents an artificial
‘‘39 extension.’’ The lN peptide, expressed as a lN-ELAV fusion
protein, binds to BoxB sequences in the luciferase transcript, thereby
tethering ELAV to the transcript in proximity to the poly(A) signal.
GFP sequences will only be expressed in the event of polymerase II
readthrough beyond the proximal poly(A) site. Primers were designed
to amplify target sequences in the luciferase andGFPORFs. (B) Extent
of poly(A) readthrough as measured by levels of GFP RNA. Luciferase
and GFP RNA levels were quantified by qPCR using primer combi-
nations shown in A. Tethering lN-ELAV, but not lN-Ago1, causes
transcription of downstream GFP sequences. Levels are shown as
GFP/luciferase ratios to normalize for transcript stability. Ratios in
cells expressing lN alone were set to the value 1. Error bars represent
mean 6 SD of four independent transfection experiments.
Hilgers et al.
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ELAV functions in a dose-dependent and promiscuous
manner to foster successive extensions in a number of
genes. In principle, ELAV can induce 39 extension in a
variety of cell types, but its activity is tightly restricted in
vivo (1) spatially, as it is present exclusively in neural
tissues; (2) temporally, as expression starts at the onset of
stage 10; and (3) in its levels—high in neurons and low in
other neural cell types.
Previous studies suggest that ELAV binds its own RNA,
and this regulation uncouples ELAV protein levels from
elav gene dosage (Samson 1998). It is interesting to note
that ELAV protein expression is tightly regulated in that
the extent of 39 extension depends on ELAV levels (Figs.
1, 3). We propose that the temporal appearance of ELAV
protein in neural tissues is responsible for the coordinate
regulation of hundreds of genes containing 39 UTR ex-
tensions. It might be an important feature of a healthy
neuron to maintain a balance between short and long
mRNA isoforms. elavmutants are embryonic-lethal, and
although neurons are generated, they do not differentiate
normally and display numerous axonal defects (Campos
et al. 1985). Such mutants contain the short forms of
target mRNAs but not the long forms. ELAV is also
required later, for neuronal maintenance: Temperature-
sensitive mutants display neuronal degeneration when
shifted to nonpermissive temperatures (Homyk et al. 1985).
Low levels of ELAV may produce insufficient amounts of
39 extended transcripts or transcripts that have not been
fully elongated. This likely contributes to elav mutant
phenotypes.
APA is a widespread mechanism for the control of gene
expression, and unbalanced APA has been associated
with human disease (Jenal et al. 2012). 39 Extensions have
been shown to be associated with neural tissues in
Drosophila (Hilgers et al. 2011), humans (Zhang et al.
2005), and zebrafish (Ulitsky et al. 2012). Several factors
are involved in neuron-specific APA in mammals. In
mice, the splicing factor Nova2 controls APA by both
repressing and enhancing poly(A) site use (Licatalosi et al.
2008). Another regulator of APA is the polypyrimidine
tract-binding protein (PTB) (Castelo-Branco et al. 2004).
Indeed, the Drosophila homologs of Nova2 (pasilla) and
PTB (heph) also exhibit APA regulation, just like elav.
In humans, three ELAV homologs, HuB, HuC, and HuD,
are selectively expressed in neurons, while HuR is ubiq-
uitous. Interestingly, in neurons, all four Hu proteins bind
to HuR mRNA to promote alternative poly(A) and gener-
ate an extended HuR 39 UTR (Mansfield and Keene 2012).
It is conceivable that the mammalian ELAV homologs
also promote coordinate 39 extension of neural-specific
mRNAs, as seen in Drosophila.
Materials and methods
Plasmids and fly strains
The elav deficiency Df(1)ED6396, UAS-GFP, and 69B-Gal4 strains were
obtained from the Bloomington Stock Center. The elav5 RNA-null mu-
tant and the transgenic line UAS-elav2e2; UAS-elav3e1 were provided by
Matthias Soller. Firefly luciferase reporter plasmids were constructed by
inserting the GFP CDS followed by the late SV40 poly(A) signal into the
XhoI–BamHI sites of pAc5.1C-FLuc-Stop-5BoxB (Rehwinkel et al. 2005).
The control plasmid lacking BoxB sites was made in the same way, using
the sites EcoRI–BamHI. To express lN-ELAV, lN-Ago1, and lN-Sxl fusion
proteins, CDSs were cloned in-frame into the EcoRI–XhoI sites of the
pAc5.1B-lN-HA plasmid. Expression of renilla luciferase was obtained
from the pAc5.1C-RLuc-V5His6 construct (Rehwinkel et al. 2005).
Cell transfection
S2 cells were transfected in six-well plates using the Effectene reagent
(Qiagen) with 300 ng of lN expression plasmid, 350 ng of firefly luciferase
reporter plasmid, and 350 ng of renilla luciferase DNA as a transfection
control. Transfections were performed with duplicate technical replicates
in four independent experiments. At 60 h post-transfection, cells were
pelleted and dissolved in TRIzol reagent (Invitrogen) for RNA extraction.
In situ hybridization and immunocytochemistry
Embryos were collected and fixed following standard procedures. All
templates for synthesis of RNA probes were obtained from PCR-amplified
genomic fragments cloned into pGEM-T Easy (Promega) and confirmed by
sequencing. For each template, antisense RNA probes were transcribed
with T7 or SP6 RNA polymerase and digoxigenin-UTP or biotin-UTP
(Roche). Embryos were hybridized with riboprobes according to standard
protocols. Detection of RNA probes was carried out with anti-digoxigenin
and anti-biotin primary antibodies and fluorescent secondary antibodies
(Invitrogen). Rat anti-ELAVwas obtained from the Developmental Studies
Hybridoma Bank (DSHB), and goat anti-HRP was a gift from Nipam Patel.
Confocal imaging was performed on a Zeiss LSM 700 microscope.
RIP
Immunoprecipitation on nuclear extracts from 8- to 12-h embryos was
performed essentially following the chromatin immunoprecipitation pro-
tocol described in Oktaba et al. (2008), with the following modifications.
Cross-linking was performed in 1.4% formaldehyde, and nuclei were
sonicated for 10 cycles of 30-sec on/30-sec off, kept on ice for 30 min, and
sonicated for five additional cycles using a Covaris S220 Ultrasonicator.
Nuclear extracts were incubated overnight with 2 mg of either amixture of
rat and mouse anti-ELAVantibodies (DSHB) or a mixture of rat and mouse
control IgG. Samples were DNase-treated (Promega) instead of RNase-
treated and were not subjected to SDS/proteinase K treatment. RNase
inhibitors (RNaseOUT, Invitrogen) were used in all steps of the protocol at
a concentration of 40 U/mL. Reversal of cross-links was performed for 1 h
at 68°C.
RNA extraction, RT, and qPCR
Total RNA was extracted from individual staged embryos, pelleted cells,
or immunoprecipitates using TRIzol (Invitrogen). RNA was treated with
RNase-free DNase (Ambion) to eliminate DNA contamination. First
strand synthesis used random hexamer primers and SuperScript III reverse
transcriptase (Invitrogen). Samples were RNaseH-treated after the RT
reaction. For qPCR, samples were used in a 1:100 dilution. qPCR was
performed and monitored in a Viia7 real-time PCR system using SYBR
Green reagents (Applied Biosystems). Primer sequences are available on
request.
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